Article Per Year (5 Year)
p-Index From 2019 - 2024
0.444
P-Index
This Author published in this journals
All Journal Jurnal Respirologi Indonesia
Amira P. Tarigan
Universitas Sumatera Utara
Health Professions Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Comparison of TGF-β Levels in Post Pulmonary Tuberculosis Patients with and Without Smoking History in Haji Adam Malik General Hospital Medan Shilvanna Litania; Amira P. Tarigan; Fajrinur Syarani
Jurnal Respirologi Indonesia Vol 40, No 3 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i3.110

Abstract

Backgrounds: Pulmonary tuberculosis (TB) and smoking related disease such as chronic obstructive of lung disease (COPD) are major health problem around the world, particularly in developing countries such as Indonesia. Chronic airway obstruction as impact of TB may results during or after completion of TB treatment. Transforming growth factor beta (TGF-β) is a cytokine which contributes to fibro genesis in post-TB treatment. The aim of this study was to compare the TGF-β in post-TB patients with and without smoking history. Methods: This was an analytic study with cross sectional design, conducted from October 2016 to February 2017 in RSUP H. Adam Malik Medan. All subjects had recovered from TB, confirmed by clinical, radiological and bacteriological examination. Smoking history of the subjects was assessed using Brinkman Index. The TGF-β measurement was performed using venous blood sample processed through Enzyme Link Immunosorbent Assay (ELISA) by means of TGF-β kit. Results: This study included post-pulmonary TB patients, of which 26 subjects were smokers and 25 were non-smokers, consisted of 31 males and 20 females. The mean TGF-β level of all samples was 6690.5±4913.4 mg/ml. The mean TGF-β level in smokers was 6621.5±4856.7 mg/ml, while in non-smokers 6762.2±5071 mg/ml. Statistical analysis using Mann-Whitney test revealed that there were no significant differences of TGF-β level in smokers and non-smokers among post-pulmonary TB patients (P=0.618). Conclusions: There were no significant differences of TGF-β level in smokers and non-smokers among post-pulmonary TB patients. (J Respir Indo. 2020; 40(3): 139-43)
The Effect of Long-Acting Beta-2 Agonist Monotherapy and Long-Acting Anticholinergic Monotherapy to Quality-of-Life in Group B Stable COPD Patients Tri Setia Negara Sinulingga; Pandiaman Pandia; Amira P. Tarigan; Putri Chairani Eyanoer
Jurnal Respirologi Indonesia Vol 42, No 4 (2022)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v42i4.370

Abstract

Background: Based on the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD), treatment for group B stable COPD patients is a long-acting beta-2 agonist (LABA) or long-acting anticholinergic (LAMA). Some studies experienced that LAMA was better than LABA but the opposite was also found in several studies. COPD patients often experience a decline in physical activity which causes a decrease in quality of life. We aimed to compare the effect of LABA or LAMA on quality of life in group B stable COPD patients.Methods: This was a study with case series design conducted on 50 COPD patients divided into two groups. The first group consisted of patients who used LABA for at least 3 months. The second group used LAMA for at least 3 months. All subjects filled in the SGRQ. The calculation of SGRQ was carried out using Microsoft Excel Calculator SGRQ.Results: A total 41 men and 9 women were enrolled in this study. There was no significant difference between the use of indacaterol monotherapy and tiotropium monotherapy on the quality of life although tiotropium showed a better quality of life (76%) than indacaterol monotherapy (64%).Conclusion: There was no significant difference in the use of indacaterol and tiotropium on the quality of life although in this case tiotropium showed better results (P=0.538).
Co-Authors Fajrinur Syarani Pandiaman Pandia Putri Chairani Eyanoer Shilvanna Litania Tri Setia Negara Sinulingga